Product Description
Pegfilgrastim Injection IP is a long-acting colony-stimulating factor prescribed to treat neutropenia (critically low white blood cell counts) caused by cancer chemotherapy. By stimulating the bone marrow to accelerate the production of neutrophilsthe white blood cells primarily responsible for fighting infectionsit helps protect your immune system and decreases the risk of developing life-threatening infections or febrile neutropenia during oncology treatments.
The "IP" designation denotes that the formulation adheres to the quality, purity, and testing specifications outlined in the Indian Pharmacopoeia.
How It Works and Is Administered
Unlike traditional filgrastim (G-CSF) injections, which frequently require daily dosing, pegfilgrastim features a polyethylene glycol ("pegylated") tail. This modification significantly delays how quickly the kidneys filter the drug out, allowing a single subcutaneous injection per chemotherapy cycle to offer complete coverage throughout your body's vulnerable window.
Timing: It is typically administered as a single dose exactly 24 to 72 hours after completing your chemotherapy infusion. It should never be administered within the 14 days leading up to your next scheduled cycle.
Method: It is strictly given as a subcutaneous injection into fatty tissue (such as the abdomen, thigh, or upper arm). It is strongly recommended to have a healthcare professional administer it, or carefully follow professional clinical training if self-injecting at home.